HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population

Onkologie

Volumn 33, Issue 4, 2010, Pages 203-204

  Berretta, Massimiliano ^a   Zanet, Ernesto ^a   Basile, Francesco ^b   Ridolfo, Anna L ^c   Di Benedetto, Fabrizio ^d   Bearz, Alessandra ^a   Berretta, Salvatore ^b   Nasti, Guglielmo ^e   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Colorectal cancer; HAART; HIV infection; Liver metastases

Indexed keywords

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; LIVER METASTASIS; PROGNOSIS; SURVIVAL RATE;

COLORECTAL NEOPLASMS; COMORBIDITY; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; PREVALENCE;

EID: 77953736610     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292126     Document Type: Letter

References (8)

1. Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25.
2. Kemeny N: Management of liver metastases from colorectal cancer. Oncology 2006;20:1161-1176, 1179, (discussion) 1179-80, 1185-1186.
3. Pozzo C, Barone C, Kemeny NE: Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat Rev 2008;34:293-301.
4. Blazeby JM, Fayers P, Conroy T, Sezer O, Ramage J, Rees M; European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group: Validation of the European Organization for Research and Treatment of Cancer QLQLMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. Br J Surg 2009;96:291-298.
5. Berretta M, Cappellani A, Di Benedetto F, Lleshi A, Talamini R, Canzonieri V, Zanet E, Bearz A, Nasti G, Lacchin T, Berretta S, Fisichella R, Balestreri L, Torresi A, Izzi I, Ortolani P, Tirelli U: Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. Onkologie 2009;32:319-324.
6. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-736.
7. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
8. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A: CPT-11 (Irinotecan) addition to bimonthly, high dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Can 1999;35:1343-1347.